US 12,144,850 B2
Methods and compositions for car T cell therapy
Philip Stewart Low, West Lafayette, IN (US); Haiyan Chu, West Lafayette, IN (US); and Yong Gu Lee, West Lafayette, IN (US)
Assigned to Purdue Research Foundation, West Lafayette, IN (US); and Endocyte, Inc, West Lafayette, IN (US)
Appl. No. 16/092,054
Filed by PURDUE RESEARCH FOUNDATION, West Lafayette, IN (US); and ENDOCYTE, INC., West Lafayette, IN (US)
PCT Filed Apr. 7, 2017, PCT No. PCT/US2017/026618
§ 371(c)(1), (2) Date Oct. 8, 2018,
PCT Pub. No. WO2017/177149, PCT Pub. Date Oct. 12, 2017.
Claims priority of provisional application 62/323,971, filed on Apr. 18, 2016.
Claims priority of provisional application 62/320,183, filed on Apr. 8, 2016.
Prior Publication US 2019/0091308 A1, Mar. 28, 2019
Int. Cl. A61K 39/00 (2006.01); A61K 9/00 (2006.01); A61K 35/12 (2015.01); A61K 35/17 (2015.01); A61K 39/395 (2006.01); A61K 47/54 (2017.01); A61K 47/55 (2017.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/44 (2006.01); C12N 15/86 (2006.01)
CPC A61K 39/0011 (2013.01) [A61K 9/0019 (2013.01); A61K 35/12 (2013.01); A61K 35/17 (2013.01); A61K 39/39558 (2013.01); A61K 47/551 (2017.08); A61K 47/555 (2017.08); A61K 48/005 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 16/44 (2013.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/16043 (2013.01)] 14 Claims
 
1. A method of treating a patient for cancer, the method comprising:
administering to the patient a chimeric antigen receptor T cell (CAR T cell) composition, wherein the CAR T cell comprises a chimeric antigen receptor (CAR) directed to fluorescein isothiocyanate (FITC), and
administering to the patient an effective amount of a first conjugate, or a pharmaceutically acceptable salt thereof, wherein the first conjugate comprises an NK-1 receptor-binding ligand (NK1RL) and FITC,
wherein the NK1RL is a small molecule comprising

OG Complex Work Unit Chemistry
wherein the CAR T cell comprises a nucleic acid comprising SEQ ID NO: 1 or SEQ ID NO: 3,
wherein the cancer is an NK-1 receptor-expressing cancer, and
wherein the patient is treated for cancer.